Specific molecular targeting of renal injury in obstructive nephropathy.
Progression of most renal disease involves tubulointerstitial injury, characterized by tubular atrophy, inflammatory cell infiltration, and interstitial fibrosis. Transforming growth factor-beta1 is central in this process. As reported by Moon et al., molecular targeting of the transforming growth factor-beta1 signaling pathway can markedly suppress renal injury resulting from unilateral ureteral obstruction, an established model of obstructive nephropathy. Specific kinase inhibitors are promising therapeutic agents to slow or attenuate progressive renal fibrosis.
Chevalier
R L
RL
Department of Pediatrics, University of Virginia, Charlottesville, Virginia 22908, USA. RLC2M@virginia.edu
D029404:Activin Receptors / Q000037:antagonists & inhibitors*; D000328:Adult; D000818:Animals; D000831:Animals, Newborn; D001284:Atrophy; D002908:Chronic Disease; D004195:Disease Models, Animal; D018450:Disease Progression; D005355:Fibrosis; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000473:pathology*; D007674:Kidney Diseases / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D007684:Kidney Tubules / Q000473:pathology; D009395:Nephritis, Interstitial / Q000473:pathology / Q000628:therapy; D010766:Phosphorylation / Q000187:drug effects; D010770:Phosphotransferases / Q000037:antagonists & inhibitors; D051381:Rats; D051900:Smad3 Protein / Q000502:physiology; D013997:Time Factors; D053773:Transforming Growth Factor beta1 / Q000502:physiology*; D014517:Ureteral Obstruction / Q000150:complications* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy
D051900:Smad3 Protein; D053773:Transforming Growth Factor beta1; D010770:Phosphotransferases; D029404:Activin Receptors